A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy
Condition: Gaucher Disease Intervention: Drug: Velaglucerase alfa Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Children With Gaucher Disease Under 5 Years Old
Condition: Gaucher Disease Intervention: Other: Standard of Care Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy
Condition: Gaucher Disease Intervention: Drug: Velaglucerase alfa Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Children With Gaucher Disease Under 5 Years Old
Condition: Gaucher Disease Intervention: Other: Standard of Care Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy
Condition: Gaucher Disease Intervention: Drug: Velaglucerase alfa Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Children With Gaucher Disease Under 5 Years Old
Condition: Gaucher Disease Intervention: Other: Standard of Care Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy
Condition: Gaucher Disease Intervention: Drug: Velaglucerase alfa Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
Phase IV Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ
Condition: Gaucher's Disease Intervention: Drug: Cerezyme® / Imiglucerase Sponsor: Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2020 Category: Research Source Type: clinical trials
